Rathore et al. noted that a combination of 5-FU, one of the standards of care in metastatic CRC treatment, and seribantumab, a HER3 targeting monoclonal antibody, had a greater effect in inhibiting tumor growth in vivo than either treatment alone [90]. The gene discussed is ERBB3; the disease is neoplasm.